A long-circulating co-polymer in "passive targeting" to solid tumors

Journal of Drug Targeting
A BogdanovR Weissleder

Abstract

A co-polymer of O-methyl polyethylene(glycol)-O'-succinate (MPEGs, m.w. 5100) and poly-l-lysine (PL, median m.w. 32700, degree of polymerization 256) has been synthesized by covalent grafting. The resultant MPEGs-PL (30% modification degree of epsilon-amino groups) had a hydrodynamic diameter corresponding to a 690 kD protein. Free amino groups (180/mol of the co-polymer) were used for conjugation of diethylene pentaacetic or succinic acid residues to MPEGs-PL. The potential of the resultant compound as a carrier of therapeutic and diagnostic drugs was studied using a rodent carcinoma models. The co-polymer had a blood pool half-life of 36h in adenocarcinoma-bearing rats. Radioactively labeled preparations were resistant to trans-chelation with apotransferrin and stable in blood for 24 h. The co-polymer accumulated in solid tumors at the level of 1.5-2% injected dose/g of tumor in 24 h. At that time, 34-40% of the accumulated polymer was associated with tumor cell fraction. The co-polymer non-covalently associated with cis-diamminedichloroplatinum(II), showed a cytostatic effect against mouse F9 carcinoma, and induced a reversal in tumor growth after intravenous administration.

References

Oct 12, 1994·Biochimica Et Biophysica Acta·V P TorchilinC A Gentry
May 1, 1993·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·T ShenT J Brady

❮ Previous
Next ❯

Citations

Aug 8, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·N Nishiyama, K Kataoka
Mar 17, 2001·Advanced Drug Delivery Reviews·K KataokaY Nagasaki
Jun 6, 2000·Advanced Drug Delivery Reviews·A A BogdanovR Weissleder
Feb 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J G ShiahJ Kopecek
Apr 15, 2009·Journal of the Royal Society, Interface·Kensuke OsadaKazunori Kataoka
Apr 17, 2010·Nanomedicine·Motoi Oishi, Yukio Nagasaki
Jan 8, 2013·International Journal of Oncology·Yan-Jun ZhongYan Li
Oct 31, 2007·Journal of Drug Targeting·Abdullah MahmudAfsaneh Lavasanifar
Dec 8, 2007·Journal of Pharmaceutical Sciences·J D G DuránA V Delgado
Jan 18, 2008·Journal of Pharmaceutical Sciences·Ales Prokop, Jeffrey M Davidson
Aug 10, 2000·Neoplasia : an International Journal for Oncology Research·A BogdanovR Weissleder
Jun 11, 2015·Scientific Reports·Gavin FullstoneGiuseppe Battaglia
Aug 31, 2004·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·Y R KimA Bogdanov
Dec 9, 2003·The Journal of Gene Medicine·Maria SimonovaAlexei Bogdanov
Aug 18, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Satya BonthaTatiana K Bronich
Aug 8, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Emiko NakamuraMasayuki Yokoyama
Feb 25, 2006·Colloids and Surfaces. B, Biointerfaces·Peisheng XuYouqing Shen
Feb 15, 2001·Investigative Radiology·M LewinG Frija
Feb 12, 2014·ACS Macro Letters·Chinessa T AdkinsEva Harth
Jun 27, 2018·Therapeutic Delivery·Lauren D FieldJames B Delehanty
Jan 31, 2012·Chemical Communications : Chem Comm·Santosh AryalLiangfang Zhang
Oct 15, 2018·Journal of Nanobiotechnology·Muhammad Raisul AbedinSutapa Barua
Dec 12, 2019·Magma·Masayuki Yokoyama, Kouichi Shiraishi
Jan 20, 2004·Cancer Research·Khalid ShahRalph Weissleder
May 4, 2002·Neoplasia : an International Journal for Oncology Research·Alexei A BogdanovRalph Weissleder

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.